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Neuroethics is an emerging ﬁeld that in general deals with the ethics of neu-
roscience and the neuroscience of ethics. In particular, it is concerned with the
ethical issues in the translation of neuroscience to clinical practice and in the pub-
lic domain. Numerous ethical issues arise when healthy individuals use pharma-
cological substances known as pharmacological cognitive enhancers (PCEs) for
non-medical purposes in order to boost higher-order cognitive processes such as
memory, attention, and executive functions. However, information regarding their
actual use, beneﬁts, and harms to healthy individuals is currently lacking. Neu-
roethical issues that arise from their use include the unknown side effects that are
associated with these drugs, concerns about the modiﬁcation of authenticity and
personhood, and as a result of inequality of access to these drugs, the lack of dis-
tributive justice and competitive fairness that they may cause in society. Healthy
individuals might be coerced by social institutions that force them to take these
drugs to function better. These drugs might enable or hinder healthy individuals
to gain better moral and self-understanding and autonomy. However, how these
drugs might achieve this still remains speculative and unknown. Hence, before
concrete policy decisions are made, the cognitive effects of these drugs should
be determined. The initiation of accurate surveys to determine the actual usage
of these drugs by healthy individuals from different sections of the society is pro-
posed. In addition, robust empirical research need to be conducted to delineate not
only whether or not these drugs modify complex higher-order cognitive processes
but also how they might alter important human virtues such as empathy, moral
reasoning, creativity, and motivation in healthy individuals. © 2014 The Authors.WIREs
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THE USE OF PCEs BY
HEALTHY INDIVIDUALS
As society becomes more dependent on technol-ogy and the boundaries between humanity and
artificial intelligence become blurred, heavy demands
are increasingly placed on the individuals’ cognitive
and physical functions. Thus among healthy individ-
uals the pursuit to enhance cognition might become
commonplace. To simply keep up with these ever
increasing demands to overproduce, healthy individu-
als are resorting to ever more creative ways of boosting
their cognition, using any means of improving their
attention.1 Recent scientific and philosophical debates
about human enhancement indicate a growing inter-
est in PCEs,2 where healthy non-sleep deprived indi-
viduals are using medications that are licensed for
patients with clinical disorders to enhance their cog-
nitive functions.1
Overview of this Paper
The aim of this paper is to give an overview of the
neuroethical issues in pharmacological cognitive
enhancement. The first section of this paper will
give an overview of the reported use of PCEs. It will
attempt to define the term cognitive enhancement and
will describe how these drugs might alter higher-order
cognitive processes. It then highlights the current
reported trends in the use of these drugs by healthy
individuals. The second section of the paper focuses on
the neuroethical issues in pharmacological cognitive
enhancement. These include the culture wars in the
cognitive enhancement debate, the advantages and dis-
advantages of using these drugs non-medically, and the
bioethical issues that might arise from their use such as
coercion, the lack of distributive justice and informed
consent, and the importance of implementing the
principles of benevolence and non-malfeasance. The
overview concludes on recommendations on how a
balanced neuroethical analysis could benefit society,
particularly the healthy individual.
WHAT IS COGNITIVE
ENHANCEMENT?
There is currently no agreed definition of the term
cognitive enhancement and it is unclear whether a
principled enhancement and/or treatment distinction
can be offered. However, the distinction between
enhancement and treatment may relate to the former
being concerned with healthy individuals attempting
to improve their cognition through neuroscientific
technologies such as the use of these drugs for
non-medical purposes while the latter is concerned
with treating patients with recognizable clinical
disorders.1 This distinction is very blurred and needs
further in-depth discussion, which is not addressed
here. However, three useful definitions of cognitive
enhancement have been proposed.
Definitions
An information-processing definition of enhancement
argues that cognitive enhancement is the amplification
or extension of core capacities of the mind through
improvement or augmentation of internal and exter-
nal information processing systems.3 A welfarist
definition of enhancement argues that enhancement
is any change in the biology or psychology of a per-
son which increases the chances of leading a good
life in the relevant set of circumstances.4 However,
bioethicists do not agree with above definitions. They
argue that enhancement is an intervention which is
beyond what is necessary to sustain good health.5,6
Because healthy individuals are using these drugs
non-medically to amplify their cognition and are in
essence going beyond what is necessary to sustain
their good health,2 PCEs can be seen as one form of
cognitive enhancement.7 Other forms of enhancement
techniques include exercise and coffee but they are
not considered here.
Pharmacological Cognitive Enhancers
(PCEs)
Current Interests
The argument that these drugs improve cognitive
performance in healthy individuals has been widely
reported in the media8 and in research.1 This has gen-
erated an increased interest among the general pub-
lic, particularly among healthy individuals who might
want to use these drugs non-medically, especially for
boosting higher-order cognitive processes.2
HIGHER ORDER
COGNITIVE PROCESSES
Executive Functions
Higher-order cognitive processes include executive
functions, which are a set of cognitive processes that
enable humans to plan ahead, solve complex prob-
lems, shift betweenmental mind-sets, inhibit unhelpful
responses, and update relevant information.9
Working Memory
Working memory is the ability to hold temporarily
relevant information active over a short interval and
to manipulate this information online.10
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Neuropsychiatric Disorders
There are primary deficits in executive functions and
working memory in a number of neuropsychiatric
disorders.11 These cognitive deficits are sometimes
a result of a traumatic brain injury or from clinical
neuropsychiatric disorders such as schizophrenia,
attention deficit hyperactivity disorder (ADHD),
Parkinson’s, or Alzheimer’s disease (AD). When these
disorders occur, the affected patients are impaired in
the capacity to plan, maintain goals, shift between
different goals, update goals in the light of new
information, and filter out irrelevant information.9
Consequently, these patients suffer from impaired
day-to-day cognitive functioning. In these patients,
drugs that pharmacologically alter neurotransmitter
modulation of cognition lead to improvements in
attention, acquisition of new information, better
executive functioning, and working memory.1 How-
ever, these drugs are reported to be increasingly used
non-medically by healthy individuals for enhancing
their cognition.2
Current PCEs
Among healthy individuals, most popular PCEs
include methylphenidate (®Ritalin), a dopamine (DA)
and noradrenaline (NA) reuptake inhibitor; dex-
troamphetamine (®Adderall), a mixed amphetamine
salt that increases DA, and is licensed for the
treatment of ADHD; and modafinil (®Provigil), a
wake-promoting drug with multiple mechanisms
of action that is licensed for narcolepsy. Other
drugs that improve cognition include atomoxe-
tine (®Strattera), a selective NA reuptake inhibitor
(SNRI); and guanfacine (®Tanex), a 𝛼2 adrenergic
agonist. Furthermore, ampakine has excitatory effects
on glutamate receptors, and induces long-term poten-
tiating processes to improve learning and memory12
in AD patients13 and in some healthy volunteers.14,15
Cholinesterase inhibitors boost acetylcholine in the
brain,13 and are moderately effective in regulat-
ing attention and memory in AD.16 In contrast,
𝛽-blockers, that are prescribed to reduce anxiety in
clinical patients, have been used by musicians to
dampen physiological tremors in order to improve
their performances on stage.17
CURRENT TRENDS IN THE USE
OF PCEs
Data from US Surveys
In the past few years, it has been reported that there
has been an unprecedented rise in the use of PCEs
among healthy university students18 and academics1
who are aiming to improve their cognitive functions.
More specifically, it has been reported that students
are specifically taking PCEs to improve academic
performance,19 and are framing their actions as
both physically harmless and morally acceptable.18
For example, in the United States, 16% of college
students20 and 8% of undergraduates reported
having illicitly obtained and used prescription
psychostimulants.21 Furthermore, a 2005 survey
by the US National Institute on Drug Abuse (NIDA)22
found that 2.5%of 13- to 14-year-olds, 3.4%of 15- to
16-year-olds, and 5.1% of 17- to 18-year-olds abused
methylphenidate. In 2009, the figures for these groups
were 1.8, 3.6, and 2.1%, respectively.23 The 2012
report by NIDA showed that non-medical use of pre-
scription and over-the-counter medicines still remain
a significant part of the teen drug problem.24 Accord-
ing to the Monitoring The Future Study, which is a
long-term epidemiological study that surveys trends in
legal and illicit drug use among American adolescents
and adults,25 14.8% of high-school seniors used a pre-
scription drug non-medically in the past year. Data for
specific drugs show that the most commonly abused
prescription drugs by teens are the psychostimulant
Adderall and the pain reliever Vicodin.24
Underachievers Using PCEs
The most recent figures show a rise in the illicit use
of PCEs among male, academically underachieving
students26 and the most up-to-date evidence suggests
that young healthy individuals are obtaining psychos-
timulant drugs from illicit sources (e.g., from others
who have prescriptions to these drugs as medications
or they are purchasing them via the internet or street
dealers).27
Problems with Epidemiological Studies
Nevertheless, these epidemiological prevalence studies
are based on survey data from college and university
students in the United States,28 and there is a lack of
evidence in the prevalence of the use of these drugs in
Europe, and more specifically in the UK. Furthermore,
these surveys do not enquire about the motivations
behind the use of these drugs. In the bioethics debate,
analysis of the current available literature suggests that
most of these drugs are being used for recreational
purposes.29 However, in the UK, a newspaper survey
of 1000 students from Cambridge University showed
that 1 in 10 were illicitly taking prescription drugs
for cognitive enhancement.30 In England, prescription
rates of psychostimulants have been rising steadily
from 220,000 in 1998 to 418,300 in 2004.31 The
reasons for this steep rise have not been explained,
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but instead it has been implicitly assumed that these
increases in prescription rates are related to emerging
PCE use for cognitive enhancement.1
Survey Responses from Academics
In 2008, the scientific journal Nature conducted a
poll about the use of PCEs by healthy academics,
to which 1400 scientists from 60 different countries
responded.32 One in five respondents used drugs for
cognitive enhancement purposes, with 52% of them
obtaining the drug by prescription, 34% obtaining the
drug via the internet, and 14% through their phar-
macy. The most popular drug was methylphenidate,
with 62% of users; 44% reported taking modafinil
mainly to improve concentration, and 15% reported
taking 𝛽-blockers for anxiety. Although this data from
these academics might be biased and unrepresenta-
tive of the general population, the figures nonetheless
suggest the increased use of PCEs among healthy aca-
demics and students.28
Currently, the global market share of modafinil
is more than US$700 million per year.33 It is now
estimated that around 90% of modafinil is predom-
inantly used off-label by healthy, non-sleep deprived
individuals who are not aiming to get ‘high’ but are
aiming to increase attention and wakefulness.34,35
Consistent with this, Greely36 previously claimed that
healthy physicians on call, students, and academics
are increasingly using PCEs to enhance cognitive
abilities. This is further supported by recent evidence
showing increased use of illicit and prescription drugs
for cognitive or mood enhancement among students
and surgeons.26,37
Fierce Academic Competition Could Lead
to Drug Use
The reported widespread use of these drugs is unsur-
prising given that the Academy of Medical Sciences38
argued that small percentage of increments in per-
formance may lead to significant improvements in
functional outcome. Indeed, they argue that a 10%
improvement in memory score could lead to an
improvement from an A grade to an A+ A-level grade
(or from a 2.1 (69%) to first class (70%) degree in the
UK). Presumably, healthy individuals are taking PCEs
to improve their academic performance.
Lack of Reliable Data and the Need
for Informative Data
However, an accurate estimation of PCE use, as well
as accurate responses of when and why healthy indi-
viduals use these drugs (e.g., to increase motivation
or attention), is currently lacking. Besides, these sur-
veys are based on academics and students’ views who
are knowledgeable about the cognitive enhancement
debate. Therefore, there is a need to conduct large
surveys on large diverse populations to establish who
takes PCEs as well as when and why they are taken.
There is also a need for empirical data on how these
drugs alter cognition and behavior in healthy individ-
uals who are using them non-medically.
Experimental Studies
In experimental settings, it is important to empha-
size that improvement from these drugs in healthy
individuals is very modest. For instance, data from
experimental laboratory studies with healthy indi-
viduals show that PCEs improve performance on
neuropsychological tasks in an inverted U-shaped
fashion, where optimal enhancement is dependent
on both dose and baseline of cognitive function.39
Small doses work best and help individuals low in
working memory.40 However, how these experimental
findings map on to the proposed definitions of cog-
nitive enhancement is unclear. The effect sizes, which
calculate the size of improvements associated with
these drugs, are rather small.41 Furthermore, these
drugs increase levels of numerous neurotransmitters
that are already at a steady level in healthy individ-
uals, and taking them might lead to over-focusing
and impairments in cognitive flexibility.42 Relevant
to the neuroethical debate, in some cases healthy
individuals even become impaired in cognition when
they take these drugs.42–48 Hence, the use of PCEs by
the healthy individuals raises numerous ethical issues,
which are discussed below.
NEUROETHICAL ISSUES
As the initial goal for prescribing these drugs was not
to improve cognitive functions in healthy individuals
with no psychiatric disorders but to treat cognitive
dysfunction in clinical patients, the non-medical use
of drugs by healthy individuals for enhancement
purposes have raised numerous ethical issues in the
emerging field of neuroethics.49 This has prompted
significant interests in academia,1 the media, and in
the public.8
What Is Neuroethics?
Neuroethics is a broad emerging field that deals with
the ethics of neuroscience and the neuroscience of
ethics.50 In particular, neuroethics is concerned with
the ethical issues in the translation of neuroscience
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to clinical practice and in the public domain.51 One
important ethical issue that neuroethics deals with is
pharmacological cognitive enhancement practices.49
This is the use of drugs, which are licensed to treat
cognitive disabilities in patients with neuropsychiatric
disorders, for improvements in cognitive function in
healthy individuals.1 As there is an absence of a clinical
disorder to ameliorate, some bioethicists argue that
the use of these drugs for enhancement purposes is
beyond what is necessary to sustain good health.5
Culture Wars in Cognitive Enhancement
Neuroethics scholars have been divided between those
who promote the use of pharmacological drugs for
cognitive enhancement7 and those who are against
this type of use.52 This divide has been termed as the
culture wars in cognitive enhancement.49 The former
scholars argue that the pursuit of cognitive enhance-
ment through drugs is permissible as long as they meet
moral acceptability criteria.49 According to Racine,49
this requires that enhancement technologies fulfill sci-
entific (e.g., risk assessment), ethical (e.g., informed
consent), social (e.g., health coverage), and regulatory
criteria (e.g., approval mechanisms). The latter group
of scholars argues that society should not engage in
pharmacological enhancement practices because pur-
suing enhancements through pharmacological means
lacks moral praiseworthiness.49
Multifaceted Nature of Brains and People
However, as cognition is multifaceted, and healthy
individuals fall into a wide spectrum of normality,
altering the healthy brain with pharmacological
agents has both advantages and disadvantages for
the individual and for society. For instance, for the
healthy individual, using these drugs for enhancement
purposes run greater risks of unanticipated health
problems,53 while for society, if PCEs increase cog-
nitive function without any significant side-effects in
healthy individuals, the benefits from enhanced cogni-
tion are substantial.54 As there are several important
considerations in the use of PCEs by healthy individu-
als, the following section discusses the general ethical
issues that have been raised in the neuroenhancement
debate. Particular attention is paid to the advantages
and disadvantages of using PCE non-medically by the
healthy.
ADVANTAGES OF USING PCEs
The advantages of using PCEs relate to the demon-
strated improvements that they have on those with
low cognitive performance.55 These advantages meet
both prudential and moral goals for the individual
and for society. For the individual, the advantages
include improved cognitive function and greater pro-
ductivity, while the advantages to society include a
more focused, more productive society, which might
mitigate societal problems, such as financial troubles
and poverty.
However, it is unclear how taking pharmaco-
logical drugs non-medically could bring about such
lofty goals. Furthermore, given that high IQ does not
increase health and wealth outcomes later in life,56
using PCEs to increase cognitive function will not
necessarily lead to a higher well-being and life sat-
isfaction. Nonetheless, these drugs boost cognition
and normalize function in patients with debilitating
neuropsychiatric disorders1 and even in healthy indi-
viduals, there is some empirical evidence showing
that those with lower baseline of working memory
performance are moderately improved by drugs like
modafinil and Ritalin.40,55 Hence, using PCEs might
be beneficial for some sectors of the population.
Self-Medication Hypothesis
It has been argued that some ‘healthy’ individuals
have undiagnosed attentional problems, and are actu-
ally self-medicating with drugs such as Ritalin.57,58
Although these individuals are self-medicating, rather
than enhancing their cognition per se, if PCEs boost
cognition in those with lower cognitive ability, there
is a good reason for their use as they have the poten-
tial benefits of removing disparities in society and in
mitigating undiagnosed neurocognitive disorders.
Social Benefits
Savulescu59 argues that human enhancement might
lead to dramatic social benefits by reducing natu-
ral inequality and promoting social justice, because
increasing cognitive ability on an individual level
could have dramatic and positive effects on society and
the economy as a whole.60 Sandberg and Savulescu54
used data simulations, and evaluated the social and
economic impact of cognitive enhancement to soci-
ety. Their analyses reveal that even small enhance-
ments to the individual and to society would have
profound positive effects. They argue that relatively
small upward shift of the distribution of cognitive abil-
ities would substantially reduce the incidence of learn-
ing problems that prevent many from flourishing, and
would help large average groups to perform better.54
To illustrate this, it has been estimated that a 3% pop-
ulation wide increase in IQwould reduce poverty rates
by 25%,61 and would lead to an annual economic
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gain of US $165–195 billion and up to 1.5% GDP
growth.62
Will PCEs Actually Improve Well-Being?
Nevertheless, it is important to note that this data is
based on simulations rather than actual evidence, and
it is not exactly clear what positive effects and what
performing better mean for healthy individuals who
are already functioning normally. The simulated data
does not show whether using PCEs will directly or
indirectly improve well-being in healthy individuals.
Again, greater economic benefits do not equal greater
well-being or happiness for society.
PCEs Are Used during Stressful Situations
Nonetheless, even healthy individuals who normally
function well, are not always performing normally
due to sleep deprivation, jet lag, or other stressors,
and some might need cognitive enhancers to perform
at their best possible level on some occasions.1 For
instance, psychostimulants have been employed to
boost cognition in military,63 soldiers in combat,64
shift workers,65 pilots,63 surgeons,66 and school pupils
diagnosed with ADHD that are performing below
average.67 The US military has been using a cognition
intervention program, which includes medications, to
enhance soldiers’ memory and cognition through tech-
nology when soldiers are under conditions of inter-
rupted sleep and stress.68 This suggests that different
sections of the population are interested in improving
their wakefulness and that using PCEs during stressful
situations might be advantageous for highly domain
specific cognitive processes. Hence, if proven to be
safe, PCEs may be utilized for improving attention
during periods of challenged sleep and stress.
Nevertheless, if one is suffering from jet lag
or insomnia, it is still unclear whether improving
wakefulness with PCEs will count as an enhance-
ment. It might be that these drugs are working to
normalize cognitive functions where they raise atten-
tion and wakefulness to one’s normal baseline level
of performance. This in itself might be an advan-
tage if one needs to boost wakefulness at a specific
or crucially important situation. However, there are
also disadvantages to using psychoactive medications
non-medically.
DISADVANTAGES OF USING PCEs
Unknown Risks
The disadvantages of using PCEs include the lack of
safety and possible harms that they might cause to
healthy individuals. For instance, the disadvantages
include greater unknown risks and long-term harms
to children and adolescents, where the brain is still
in development.7 Lewens69 succinctly addresses the
substantial risks associated with pharmacological cog-
nitive enhancement practices and, using a bioethical
precautionary principle6 evaluates their benefits and
risks. Based on such analysis, Lewens69 objects to the
uses of these drugs on the basis that their benefits to
healthy individuals are small and they carry the sub-
stantial risks of causing harm to healthy individuals.
Coercion in Children
Singh et al.70 discuss specific ethical issues that arise
from neuroenhancement in young children. These
include lack of capacity to consent, and coercion from
teachers and parents. However, even in healthy adults
who can consent, the same safety concerns still arise,
as these drugs carry risks and side-effects that might
outweigh the beneficial effects of their use.1 Exposing
psychoactive agents to the healthy brain runs the risk
of damaging receptors that allow smooth communica-
tions between neurons in the brain.13 Using a pharma-
cological agent could also lead to a neurotransmitter
imbalance in specific parts of the healthy brain, which
can lead to long-term detrimental effects.71
Neurotransmitter Imbalance in ADHD
A good example in this neurotransmitter imbal-
ance is the case of ADHD disorder, which has
been implicated in structural abnormalities in the
fronto-striato-circuitry72 and dysfunctions in cate-
cholamine neurotransmission, specifically in the NA
and DA pathways in the prefrontal cortex.73 This
dysfunction leads to inefficient information process-
ing and hypo-activation in the frontal lobes.13 As a
result, patients diagnosed with ADHD have significant
impairments in executive functions andworkingmem-
ory performances.74
Safety Concerns for Healthy Individuals
However, it is currently unclear whether exposing the
healthy brain to pharmacological agents for neuroen-
hancement purposes could result in this very dys-
function in catecholamine neurotransmission that is
reported in the ADHD disorder. These safety concerns
are amplified in the absence of informative data from
healthy individuals. Accordingly, Lewens69 predicts
that the use of these drugs for enhancement purposes
carry substantial risks to health. However, it is impor-
tant to note that Lewens’69 arguments are based on
potential substantial risks to the health of the healthy
individuals which currently there is no data. It would
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be ideal to specify the probability of these risks occur-
ring in healthy individuals.
The Abuse Liability of PCEs
Notwithstanding these points, all drugs have side
effects. Yet, while in patients the benefits of using cog-
nitive boosting drugs often outweigh the side-effects,75
in healthy individuals, the risks include possible
unknown, long-term negative consequences, includ-
ing personality change and addiction.52 The abuse lia-
bility of some of the PCEs such as methylphenidate
and modafinil is also increasing, which is becoming
a concern. For example, a recent study showed that
modafinil blocked DA transporters and increased DA
in the caudate, putamen, and nucleus accumbens in
healthy human brains.76 These are well-known areas
in a network known to be involved in drug-seeking
behavior and addiction.48 This indicates the need for
awareness about the risks involved in PCE use among
healthy individuals, and shows that a full ethical con-
sideration of their use is required.
Lack of Longitudinal Data on the Abuse
Potential of PCEs
To date, there have not been systematic randomized
psychopharmacological trials investigating the short-
and long-term use, as well as the positive and neg-
ative effects of PCE drugs on healthy individuals.1
Thus, without any concrete evidence on their cognitive
enhancing effects and safety profile, using the precau-
tionary principle is prudentially useful.6 For instance,
it could be argued that their use can be objected to
on the basis that they might cause risks and harms to
healthy individuals. Furthermore, if doctors prescribe
these drugs for enhancement purposes, healthy indi-
viduals might find it difficult to make informed and
autonomous decisions onwhether the risks involved in
neuroenhancement outweigh the purported benefits.
There are still further safety concerns about the risks
of ingesting toxic or impure substances that are adver-
tised as PCEs and are purchased over the internet.
UNINTENDED CONSEQUENCES
The disadvantages associated with the use of PCEs
also include unintended consequences that may result
from their use. Adderall has been shown to impair
creativity performance in healthy individuals high in
creativity.77 Furthermore, DA agonist, bromocriptine,
improved the performance of executive function tasks
in individuals with lower than average working mem-
ory capacity, but impaired performance of those with
high working memory capacity.78 Recent evidence
suggests that in non-ADHD adults PCEs may actually
impair performance of tasks that require adaptation,
flexibility, and planning.42
Cognitive Trade-Offs
A recent double blind placebo-controlled study with
children diagnosed with ADHD disorder showed that
methylphenidate increased perseverative errors in the
Wisconsin Card Sorting Test,79 a task of cognitive
flexibility and set shifting. One might argue that
cognitive flexibility is an important cognitive pro-
cess and constricting it with psychoactive drugs in
healthy individuals and in patients diagnosed with
ADHD could be problematic both for individuals
and for society.80 As mentioned above, research indi-
cates that off-label psychostimulant use, including
methylphenidate, is highest in US college students,81
but this off-label use has been reported to nega-
tively affect subjective sleep quality82 and to increase
depressive mood in this particular cohort.21 This is an
example of PCEs having unintended consequences in
healthy individuals. As these drugs are not licensed for
enhancement use and are not prescribed by a qual-
ified doctor they might not be suitable for healthy
individuals.
Contraindications
For instance, contraindications of atomoxetine
and modafinil include heart problems and hepatic
impairments.83 Additionally, if one is taking other
medications there might be drug–drug interactions,
which could be dangerous in some cases. On the
other hand, if these children find it difficult to focus,
the drug might help them concentrate better and
might enable them to achieve important life goals
such as obtaining a college or a university degree.
In any case, given that the way these drugs change
cognitive processes are currently not well delineated,
their effects on cognition and behavior could lead
to both good and bad unintended and unanticipated
consequences.
COERCION
Healthy individuals might be coerced to use PCEs.
Coercion typically carries the important implications
of diminishing the targeted agent’s freedom and
responsibility, and that it is pro tanto wrong because
it violates personal autonomy.84 There are ethical
concerns about healthy individuals being coerced into
using PCEs to enhance their abilities. Society might
Volume 5, September/October 2014 © 2014 The Authors. WIREs Cognitive Science published by John Wiley & Sons, Ltd. 539
Overview wires.wiley.com/cogsci
force healthy individuals to take psychoactive agents
in order to perform better, or to be in a particular
mental state. For example, authorities in the United
States ordered a mentally ill inmate, in criminal pro-
ceedings, to take psychotropic medications to improve
his competence to stand trial and be executed.85,86
This illustrates an example in which PCEs can be
used coercively and can raise considerable ethical and
moral problems for society.
Social Coercion
There is also considerable potential for indirect coer-
cion resulting from a highly demanding ‘24/7 society’
where healthy individuals feel compelled to take PCEs
in order tomeet social or workplace demands. Healthy
individuals may resort to self-medication for inade-
quate sleep or overexertion at work. For example,
33% of respondents of the poll by Nature indicated
that they would feel pressure to give PCE drugs to
their children if other children at school were taking
them.32 There might still be social pressures to use
PCEs, particularly in young people. Riis et al.’s87 sur-
vey revealed that US college students are more likely
to take PCE drugs if such drugs were effective, and
were framed as non-threatening to their individuality.
Therefore, this raises the ethical issue that arises from
the use of PCEs because of social pressure, nudging,
or indirect suggestions to try to achieve non-forced
compliance and clever marketing of drugs for
non-medical use.
Ethical Blind Spots in Mislabeling
Medication Drugs
Forlini and Racine88 argue that the medical commu-
nity and the media have already contributed to the
misconception of terming prescription drugs as ‘mira-
cle drugs’ and this has misled lay people into thinking
that these drugs are ‘smart drugs’, enhancing every-
body without side effects. According to them, this cre-
ates an ethical blind spot that masks the importance
of investigating the long-term harm and side effects of
PCEs in healthy individuals. They argue that describ-
ing the phenomenon as ‘enhancement’ does not do
justice to the unknown risks of long-term non-medical
use of prescription drugs as this has generated many
polarized debates, framed in terms of ‘to enhance or
not to enhance’, while paying less attention to the con-
ditions under which enhancement of function could
become ethically acceptable. They further argue that
framing the use of PCEs by healthy individuals as
‘lifestyle’ contributes to the ethical blind spots that
indirectly coerce people to take PCEs. Other promi-
nent bioethicists share this view, and argue that call-
ing these drugs cognitive enhancers will inevitably
lead to overuse, abuse, and addiction in healthy
individuals.52
Cognitive Liberty
In contrast, other ethicists argue for the existence of
strong negative right to cognitive enhancement, where
individuals exercise cognitive liberty, privacy interest,
and interest of persons in protecting and developing
their ownminds and capacity for autonomy.85 In prac-
tical ethics, one would argue that healthy individu-
als are free to take or not to take PCEs because they
are autonomous. However, Merkel et al.89 argued that
refusing to be part of a (pharmacologically) enhanced
society, and thus staying ‘natural’, would mean inten-
tionally choosing to live one’s life at a lower base-
line of functioning than the average person. However,
some individuals choose not to take PCEs and yet can
still function well, so the argument that everyone will
be enhanced if they took PCEs is not tenable sim-
ply because these drugs do not have the same effect
on cognition in all individuals. Some individuals will
benefit from a drug and others will not, and some
might even become impaired in cognitive function. As
discussed earlier, experimental studies on psychostim-
ulants support the view of baseline dependency for
cognitive improvement.
Low Cognitive Function and PCEs
Research is corroborating the evidence that individ-
uals with low working memory capacity may bene-
fit from PCEs while high working memory capacity
individuals are over stimulated and, in some cases,
show deterioration in cognitive performance.39,55 Fur-
thermore, many null and negative results are not
reported in the literature, which suggests that the
cognitive enhancing effects of PCEs are even smaller
than the positive results that have been consistently
reported.
AUTHENTICITY
Authenticity is a complex concept that is multidimen-
sional but it essentially means that the individual expe-
riences their true, natural self without feeling alienated
and psychologically, socially, spiritually, or existen-
tially coerced.90
Ethicists argue that memory modification
through PCE use poses a threat to authenticity91,92
in that modifying our inherent self, character, and
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individuality poses the threat of what it means to be a
human being.53 It is important to distinguish between
two concerns of authenticity. One concern relates to
being authentic to one’s true individual self,93 while
another relates to staying human, or retaining what is
valuable in our humanity. For some bioethicist, there
is the worry that using PCEs will change our natural
tendencies that might lead us, in the outset, to believe
that our emotions need altering with PCEs (e.g.,
using 𝛽-blockers to dampen physiological tremors
in order to improve performances on stage). For
example, when we feel sorrow, or emotions that serve
important functions, such as feeling empathy toward
others, it is by no means clear that we would be better
off without such emotions. Kass6 argues that: ‘the
lack of “authenticity” sometimes complained of in
these discussions is not so much a matter of “playing
false” or of not expressing one’s “true self,” as it is a
departure from “genuine,” unmediated, and (in prin-
ciple) self-transparent human activity’. Thus, there
is a concern that PCEs will threaten our notion of
personhood and will dampen essential characteristics
of what it means to be human.53 In this context, the
notion of personhood is related to what makes us
who we are as humans, as opposed to the subsets
of characteristics related to our rational capacities
that can be argued to be related to our developed
brains.
Altering Self-Identity Versus
Cognitive Performance
Consistent with this view, the study by Riis et al.,87
which investigated the preferences for psychological
enhancements by young Americans, found that young
healthy individuals are not interested in enhancing or
altering traits that are fundamental to self-identity,
including motivation and social skills, as opposed to
mental faculties like memory, ability, and concentra-
tion. Hence, healthy individuals might object to using
PCEs if they impair important human characteristics
such as authenticity, creativity, and other traits related
to self-identity.80
Technology and Authenticity
Other philosophers argue that new technologies, such
as PCEs, which alter the self, need not be threatening
to the authentic self, but rather might bring the
actual self in line with the ideal self. For this reason,
Levy94 argues that enhancement technologies can be
seen as enhancing our authenticity. If PCEs are safe
and effective, we might not object to utilizing them
as a form of cognitive enhancement, and as Levy94
argues, using PCEs might be a way of developing our
authentic self and might aid both our self-discovery
and self-creation. Indeed, some patients diagnosed
with ADHD feel as though their true self emerges only
while on medication, while others feel a loss of self
while on medication.95
Undervaluing Work and
Personal Achievement
However, although philosophers might argue that
using drugs for enhancement can aid authenticity,
public health researchers do not agree with this
account and might object to their use.52 If healthy
individuals take drugs that focus their attention
and memory, could their perception of themselves
change from being human to being mechanistic
beings with a modicum of emotions? Farah et al.53
also argue that using neuroenhancers could under-
value hard work and achievement. Similarly, children
diagnosed with ADHD have been shown to give
excuses for, and attribute bad behavior to forgetting
to take psychostimulants, rather than to their own
behavior.70,96 In contrast, parents have been shown
to attribute positive behaviors to psychostimulant
use.97,98 Therefore, it is arguable that, because chil-
dren are attributing their bad behavior due to not
taking psychostimulants, using psychostimulants pose
threats to self-identity and the understanding of moral
agency. However, Singh et al.70 argue the opposite and
show that the use of psychostimulants in children can
positively contribute to their moral self-understanding
and self-identity. Singh99 recently used an empirical
approach to evaluate the claim whether psychostimu-
lant drugs pose threats to authenticity and to children’s
capacity for moral agency. Drawing on empirical data
from studies involving families in the United States
and UK, Singh99 shows that, although children
are able to report threats to authenticity related to
psychostimulant drug treatments, the majority of chil-
dren are not concerned with such threats. On balance,
Singh99 argues that children report that psychostim-
ulant drugs improve their capacity for moral agency,
and they associate this capacity with an ability to meet
normative expectations. Singh99 further argues that
this association raises an important question about
whether the use of psychostimulant drugs in children
in fact threaten the capacity to protest bad conditions
and, as a consequence, allows bad conditions to
prevail. Singh99 suggest that medical professionals
should play a role in ensuring that the risks of psy-
chostimulant drug treatment are minimized, and the
benefits are maximized. A further issue is how insight-
ful children are in attributing their good behavior to
taking psychostimulants, given that their responses
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might be based on conforming to and feeling good
about fitting within social norms and expectations.
It also raises questions regarding as to what extent
doctors might become complicit in giving children
medications to behave better and, as a consequence,
might further perpetuate unhealthy norms in society.
Hence, from this analysis, the use of PCEs in young
healthy individuals has implications for authenticity,
individuality, and personal identity. Using PCEs will
have an impact on how we relate to them, how they
think of their behavior and, more importantly, their
individuality and moral understanding.
DISTRIBUTIVE JUSTICE AND
COMPETITIVE FAIRNESS
Disparities in Society
Another argument against the use of PCEs is that, if
only the wealthy can access them, they might further
exacerbate the ever-growing inequality in society.100
This raises questions about distributive justice, where
the uses of enhancement technologies in general, and
PCEs in particular, might divide those who have access
from those who have not. The disparities in access to
a potentially cognitive boosting drug might increase
injustice.91 This is particularly relevant, given the
argument that small cognitive improvements can lead
to significant academic gain.38 If this is the case, using
PCEs to improve academic performance could lead
to even more disparities in academic attainment. A
recent survey of University of Cambridge students
indicated that students are opposed to using PCEs
because of the potential risks that they might cause to
healthy individuals and the inequality of access which
might lead to disparity in academic performance.101
These views were similar to Australian students who
expressed strong objections to the uses of these drugs
in academic contexts.102
CHEATING
As discussed above, whether the use of PCEs con-
stitutes cheating becomes relevant. For instance, is it
morally justified to use PCEs during exams, and does
it give the user an unfair advantage over those who
are equally capable but are not using PCEs? This is
particularly important since young healthy individu-
als in the United States are more willing to use PCEs to
enhance their cognition, especially if PCEs allow them
to gain an unfair advantage over others.87 The issue
of cheating has been frequently debated in the cog-
nitive enhancement literature. By definition, cheating
constitutes violating the rule that these drugs should
be gained through prescription by only for those
with clinical and neuropsychiatric disorders. One way
that cheating has been argued to be unethical is that
cheaters break rules in order to gain an unfair advan-
tage over others.103 For this reason, it has been argued
that using drugs for enhancement purposes during
academic examinations is a form of cheating.103
Lack of Clear Academic Policy
However, many universities have no formal policy
about the off-label uses of PCEs during exams.1
Nevertheless, if PCEs enable individuals to compete
better than those who do not have them, it can be
argued that PCE users are gaining positional goods
because they have the competitive advantage that
depend on others not having access to PCEs104 and,
therefore, their use constitutes to cheating.103 If this is
the case, then the problem of cheating can be remedied
by either changing the rules, or by instituting controls
and sanctions against the use of PCEs.103
Violating Internal Goods and Standards
of Excellence
However, even if this does not lead to banning PCEs,
another objection to using PCEs, at least in aca-
demic contexts, is that it violates ‘practices’ with their
own internal goods and standards of excellence. For
instance, it might violate the practice of honestly striv-
ing to study for exams and working hard. Neverthe-
less, although healthy individuals are currently not
breaking explicit rules, as there is currently no policy
against the use of PCEs for academic purposes, by tak-
ing PCEs to perform better in exams, they are breaking
the implicit rule of the practice of fair competition,
hard and honest work. As a result, they might be gain-
ing a competitive advantage over others who are not
taking them.
INFORMED CONSENT
If the full mechanisms of these drugs are not well
known can healthy individuals be consenting to the
use of these drugs when doctors prescribe them for
enhancement purposes? Children under 16 years of
age cannot consent to the use of PCEs, while ado-
lescents might not have the full capacity to make
an informed decision about the consequences of
using psychoactive drugs for cognitive enhancement.
Informed consent is likely to raise different ethical
issues in the enhancement field as opposed to the
treatment field. The ethical issues about consenting to
taking drugs for medications are far more developed
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than in cases where young children are illicitly taking
medications for enhancement. Hence, another ethical
issue that is relevant to taking PCEs for enhancement
purposes relates to whether healthy individuals, espe-
cially when they are young, are exercising their full
informed consent when doctors prescribe these drugs
for enhancement purposes.
Autonomy
Bioethicists argue that healthy individuals are
responsible for their actions, and therefore we
ought to expect that they know the consequences
of using PCEs. Glannon5 argues that, as autonomous
individuals, healthy individuals have the right to
use PCEs, as long as they do not harm others, and
they access these drugs on their own (without being
coerced). Glannon5 also argues that if these drugs
cause harm to healthy individuals, they can be banned
on public health (paternalistic) grounds. However, for
healthy individuals to exercise their informed con-
sent, it might be necessary to provide full information
about how these drugs work on their body and brains.
BENEFICENCE AND
NON-MALFEASANCE
Enhancing the brain, with its higher cognitive pro-
cesses, demands strong ethical and practical policy
considerations. An important ethical issue that can
arise from neuroenhancement relates to the risks and
harm that can result from their use by healthy indi-
viduals. Hence, a clear consideration of the benefits
and harms of the use of these drugs in healthy indi-
viduals is required. Although neither the British Psy-
chological Society105 nor the American Psychologi-
cal Association106 have specific ethical guidelines for
the use of PCE drugs, both bodies have put forward
the principle of placing greater responsibility to limit
detrimental effects to animals and human volunteers.
These guidelines can be extended to limit the possi-
ble risks associated with the use of drugs for cognitive
enhancement purposes. Thus, the principles of benefi-
cence and non-malfeasance can preserve autonomy on
moral and prudential grounds. This means that soci-
ety can implement policies that safeguard individuals
while individuals resist social coercion and exercise
responsibility to oneself and obligations to society.107
Enhancement Policy Criterion
Bostrom and Roche108 argued for the need to estab-
lish a baseline for acceptable risks involved in cogni-
tive enhancement. Glannon5 asserts that, with PCEs,
such acceptable risks should include a benefit ratio
for healthy individuals; if using PCEs pose risks of
adverse effects in the central nervous system and the
benefits are modest, there is no justification for doc-
tors prescribing them to healthy individuals.5 Thus,
for further decision making, an enhancement policy
criterion could be that before PCE drugs are pre-
scribed off-label to healthy individuals, their cognitive
enhancing effects and their effectiveness must be fully
tested to provide important facts about their benefits.1
To provide this, scientific studies need to be carefully
conducted with each putative cognitive enhancer and
the empirical results should be reported. Moreover,
empirical studies that focus on understanding one
specific PCE which alongside analyse the ethical issues
that might arise from such PCE use need to be con-
ducted. Such comprehensive understanding of a par-
ticular PCE would inform both the neuroscience and
neuroethics of cognitive enhancement. This approach
would enable researchers, clinicians, parents, teach-
ers, policy makers, and regulatory bodies to evaluate
whether each PCE has beneficial or detrimental effects
on diverse cognitive functions that might have positive
or negative implications for optimal well-being and
functioning. This will contribute toward the reduction
of harm and in the promotion of the well-being of
healthy individuals who want to use these drugs for
cognitive enhancement.
GENERAL CONCLUSIONS
This article gave an overview of the current neuroethi-
cal issues that arise when healthy individuals use phar-
macological substances as a way of enhancing cogni-
tive processes. It is clear that there are several gray
areas in the neuroethical issues that arise from the use
of drugs for cognitive enhancement purposes. Most
pressing neuroethical issues include the lack of accu-
rate information regarding their actual use, their bene-
fits and harms to healthy individuals, including young
children; it is clear that the use of drugs for enhance-
ment purposes carry substantial unknown risks to the
healthy individual, such as the negative side effects
that they might have on the healthy brain. There are
also concerns that they might alter authenticity and
personhood in the healthy individual. Hence, these
drugs might enable or hinder children and healthy
adults to gain better moral and self-understanding and
autonomy. Although current evidence suggests that
these drugs have small effects on cognition in healthy
individuals, if in the future they actually improve cog-
nition they might have implications on distributive
justice and competitive fairness, in that they might
exasperate the inequality of access that can arise from
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enhanced cognition and well-being in those who have
access to these drugs. Other neuroethical issues that
arise in neuroenhancement relate to healthy individu-
als being coerced by social institutions that force them
to take cognitive enhancing drugs to function better.
However, before concrete ethical claims and practical
policies can bemade, the cognitive enhancing effects of
these drugs should be determined. It is of paramount
importance that accurate surveys are conducted to bet-
ter determine actual usages of these drugs by healthy
individuals from different sections of society. In addi-
tion, robust empirical research needs to be conducted
to delineate not only how these drugs modify mem-
ory, attention, and executive functions but also how
they alter important human virtues such as empathy,
moral reasoning, creativity, and motivation in healthy
individuals. Finally, this overview did not address the
underlying motivations of different stakeholders who
are either promoting or opposing the use of drugs for
neuroenhancement purposes. It could be argued that if
these motives are not based on the principles of benef-
icence and non-malfeasance they may themselves raise
ethical issues that merit thorough neuroethical analy-
sis and discussion.
CONCLUSIONS
The use of pharmacological agents for cognitive
enhancement purposes has been one of the most fre-
quently talked about issue in the cognitive neuro-
sciences, philosophy, and in the media. There are polar
views onwhether or not healthy individuals should use
these drugs for cognitive enhancement purposes. Some
scholars are currently staunch advocates of pharmaco-
logical cognitive enhancement while others are com-
pletely opposed to it. This has created what is known
as the culture wars in cognitive enhancement. What
is clear from this overview is that the empirical evi-
dence to support the cognitive enhancing effects of
pharmacological agents in otherwise healthy individ-
uals is inconclusive. The neuroethical issues that arise
from their use are also numerous and are tinged with
clashes in opinion and the advocacy of specific points
of views. The culture wars in cognitive enhancement
may itself pose an ethical issue as it hinders proper and
honest dialog in the field. Therefore, it might be useful
that researchers, clinicians, parents, teachers, policy
makers, and regulatory bodies initiate more balanced
and unbiased dialogs that aim to evaluate whether
or not PCEs have beneficial or detrimental effects on
diverse cognitive functions and well-being in healthy
individuals. This will contribute toward the reduction
of harms and in the promotion of well-being of healthy
individuals who are interested in using these drugs for
cognitive enhancement. This article has contributed to
this dialog by giving an overview of the diverse neu-
roethical issues in the use of pharmacological drugs for
cognitive enhancement by healthy individuals. In con-
clusion, it is important to evaluate each specific puta-
tive PCE, both empirically and ethically, before reject-
ing it or advocating for its use for enhancement pur-
poses. Such evaluation is a worthy pursuit that offers
an alternative option to the culture wars in cognitive
enhancement. Finally, attempting this interdisciplinary
endeavor would indeed advance both the emerging
field of neuroethics and the more advanced field of
cognitive neuroscience.
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